Nifty
:
25461.00
Sensex
:
83432.89
55.70 (0.22%)
193.42 (0.23%)
Nifty
Sensex
:
:
25461.00
83432.89
55.70 (0.22%)
193.42 (0.23%)

Zim Laboratories Ltd.

Pharmaceuticals & Drugs

Rating :
50/99

BSE: 541400 | NSE: ZIMLAB

NSE BSE
110.89
04-Jul-2025
  • Open
  • High
  • Low
  • Previous Close
  •  107.83
  •  111.89
  •  107.83
  •  107.83
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  53137
  •  5830585.33
  •  128.9
  •  79.49

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 539.39
  • 44.34
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 648.95
  • N/A
  • 2.15

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 33.26%
  • 7.54%
  • 47.78%
  • FII
  • DII
  • Others
  • 0.01%
  • 0.00%
  • 11.41%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 3.51
  • 4.29
  • -1.66

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 4.12
  • 1.92
  • -3.40

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 9.08
  • 10.68
  • -20.75

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • 28.86
  • 29.09

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • 1.84
  • 2.25

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • 9.60
  • 11.13

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Var%
Dec 24
Dec 23
Var%
Sep 24
Sep 23
Var%
Jun 24
Jun 23
Var%
Net Sales
108.73
117.86
-7.75%
96.33
96.29
0.04%
92.14
85.83
7.35%
81.82
67.44
21.32%
Expenses
94.14
102.22
-7.90%
84.77
84.76
0.01%
82.61
76.50
7.99%
73.79
62.61
17.86%
EBITDA
14.60
15.65
-6.71%
11.56
11.53
0.26%
9.53
9.32
2.25%
8.04
4.83
66.46%
EBIDTM
13.42%
13.28%
12.00%
11.98%
10.34%
10.86%
9.82%
7.16%
Other Income
1.71
1.53
11.76%
1.76
1.11
58.56%
1.32
1.42
-7.04%
1.00
1.12
-10.71%
Interest
2.91
2.28
27.63%
2.73
1.70
60.59%
2.89
1.22
136.89%
2.86
1.73
65.32%
Depreciation
5.29
3.90
35.64%
4.88
3.94
23.86%
5.00
4.09
22.25%
4.94
4.03
22.58%
PBT
8.11
11.00
-26.27%
5.70
7.02
-18.80%
2.96
5.44
-45.59%
1.23
0.19
547.37%
Tax
3.22
2.91
10.65%
1.70
2.23
-23.77%
0.58
1.29
-55.04%
0.34
-0.04
-
PAT
4.88
8.09
-39.68%
4.00
4.79
-16.49%
2.38
4.15
-42.65%
0.90
0.23
291.30%
PATM
4.49%
6.86%
4.15%
4.97%
2.58%
4.83%
1.10%
0.34%
EPS
1.00
1.66
-39.76%
0.82
0.98
-16.33%
0.49
0.85
-42.35%
0.18
0.05
260.00%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Net Sales
-
379.03
367.42
398.53
333.43
307.26
277.74
335.37
272.80
235.01
268.51
Net Sales Growth
-
3.16%
-7.81%
19.52%
8.52%
10.63%
-17.18%
22.94%
16.08%
-12.48%
 
Cost Of Goods Sold
-
167.85
171.44
198.83
160.35
158.63
143.14
159.51
140.89
119.96
157.72
Gross Profit
-
211.18
195.98
199.69
173.08
148.63
134.60
175.86
131.91
115.04
110.79
GP Margin
-
55.72%
53.34%
50.11%
51.91%
48.37%
48.46%
52.44%
48.35%
48.95%
41.26%
Total Expenditure
-
335.30
326.09
346.54
292.45
267.50
255.13
293.34
238.02
203.53
239.32
Power & Fuel Cost
-
17.39
13.47
11.09
9.14
7.04
7.47
7.19
5.75
5.35
6.40
% Of Sales
-
4.59%
3.67%
2.78%
2.74%
2.29%
2.69%
2.14%
2.11%
2.28%
2.38%
Employee Cost
-
60.76
53.34
49.32
40.07
35.76
35.35
48.26
40.80
33.00
30.70
% Of Sales
-
16.03%
14.52%
12.38%
12.02%
11.64%
12.73%
14.39%
14.96%
14.04%
11.43%
Manufacturing Exp.
-
38.37
39.34
33.83
29.03
23.40
26.97
13.62
7.82
7.76
7.25
% Of Sales
-
10.12%
10.71%
8.49%
8.71%
7.62%
9.71%
4.06%
2.87%
3.30%
2.70%
General & Admin Exp.
-
20.21
17.98
19.55
15.82
10.72
11.61
14.53
10.85
10.30
8.61
% Of Sales
-
5.33%
4.89%
4.91%
4.74%
3.49%
4.18%
4.33%
3.98%
4.38%
3.21%
Selling & Distn. Exp.
-
24.12
24.48
27.94
32.70
27.96
24.51
45.61
28.22
22.53
22.04
% Of Sales
-
6.36%
6.66%
7.01%
9.81%
9.10%
8.82%
13.60%
10.34%
9.59%
8.21%
Miscellaneous Exp.
-
6.61
6.04
5.98
5.35
3.98
6.07
4.62
3.69
4.62
22.04
% Of Sales
-
1.74%
1.64%
1.50%
1.60%
1.30%
2.19%
1.38%
1.35%
1.97%
2.46%
EBITDA
-
43.73
41.33
51.99
40.98
39.76
22.61
42.03
34.78
31.48
29.19
EBITDA Margin
-
11.54%
11.25%
13.05%
12.29%
12.94%
8.14%
12.53%
12.75%
13.40%
10.87%
Other Income
-
5.78
5.18
6.41
4.40
2.34
4.52
2.05
3.42
5.51
3.91
Interest
-
11.39
6.92
5.58
8.31
10.90
12.65
10.59
9.34
10.47
13.65
Depreciation
-
20.11
15.95
17.47
16.03
15.79
14.41
11.42
9.79
9.02
8.76
PBT
-
18.01
23.64
35.35
21.04
15.41
0.07
22.07
19.07
17.50
10.69
Tax
-
5.84
6.40
10.92
6.49
2.91
-3.23
6.73
5.83
-1.09
0.26
Tax Rate
-
32.43%
27.07%
30.89%
30.85%
28.45%
-4614.29%
30.49%
23.39%
-6.23%
4.85%
PAT
-
12.16
17.25
24.43
14.55
7.32
3.30
15.34
19.11
18.59
5.10
PAT before Minority Interest
-
12.16
17.25
24.43
14.55
7.32
3.30
15.34
19.11
18.59
5.10
Minority Interest
-
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
-
3.21%
4.69%
6.13%
4.36%
2.38%
1.19%
4.57%
7.01%
7.91%
1.90%
PAT Growth
-
-29.51%
-29.39%
67.90%
98.77%
121.82%
-78.49%
-19.73%
2.80%
264.51%
 
EPS
-
2.50
3.54
5.02
2.99
1.50
0.68
3.15
3.92
3.82
1.05

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Shareholder's Funds
252.24
238.75
200.35
175.71
160.75
153.82
151.12
136.60
118.33
98.96
Share Capital
48.73
48.73
48.73
16.24
16.24
16.18
16.12
8.06
8.03
8.00
Total Reserves
202.16
190.02
151.62
159.47
144.51
137.28
133.77
127.95
109.59
90.34
Non-Current Liabilities
53.42
48.65
30.45
20.01
19.40
22.72
20.19
16.61
18.09
34.75
Secured Loans
40.30
35.60
24.62
18.92
21.83
27.01
19.14
15.91
26.75
33.98
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
0.41
3.02
4.37
0.77
0.77
Long Term Provisions
0.00
0.00
0.00
0.00
0.01
0.00
0.10
0.00
0.00
0.00
Current Liabilities
166.36
159.43
110.79
147.37
142.04
143.44
156.40
141.40
113.21
123.65
Trade Payables
69.51
62.38
58.24
81.07
64.87
66.00
71.95
66.26
45.05
46.97
Other Current Liabilities
40.80
41.21
29.07
44.71
31.16
26.68
38.65
25.15
18.33
16.71
Short Term Borrowings
52.46
55.04
22.88
17.34
44.60
49.69
40.15
49.56
46.70
56.30
Short Term Provisions
3.60
0.80
0.59
4.24
1.40
1.06
5.65
0.43
3.14
3.68
Total Liabilities
472.02
446.83
341.59
343.09
322.19
319.98
327.71
294.61
249.63
257.36
Net Block
164.28
160.83
108.66
105.64
106.52
115.92
106.01
94.16
88.75
92.19
Gross Block
274.88
266.57
198.66
180.24
165.49
159.23
135.67
112.90
97.77
120.36
Accumulated Depreciation
110.61
105.74
90.01
74.60
58.97
43.31
29.66
18.74
9.02
28.17
Non Current Assets
240.72
219.17
150.63
129.49
130.43
137.94
132.39
121.68
95.86
102.02
Capital Work in Progress
70.46
42.28
26.99
11.74
10.68
9.62
13.32
8.29
3.82
2.93
Non Current Investment
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
Long Term Loans & Adv.
5.16
15.71
14.41
11.78
11.32
10.40
11.72
17.33
2.35
6.36
Other Non Current Assets
0.76
0.31
0.52
0.28
1.85
1.95
1.29
1.84
0.87
0.48
Current Assets
231.31
227.65
190.95
213.59
191.76
182.03
195.32
172.94
153.77
155.34
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
86.47
81.26
53.71
75.28
54.35
56.39
55.05
51.56
35.47
37.72
Sundry Debtors
106.92
100.17
95.25
89.52
72.25
67.93
93.10
89.22
88.18
88.53
Cash & Bank
2.49
10.46
7.52
4.97
8.35
3.95
2.94
3.53
5.61
6.39
Other Current Assets
35.43
2.29
2.56
1.41
56.81
53.76
44.23
28.63
24.52
22.70
Short Term Loans & Adv.
32.33
33.46
31.91
42.41
55.26
52.16
42.83
27.51
23.51
21.49
Net Current Assets
64.94
68.22
80.16
66.23
49.72
38.60
38.92
31.54
40.56
31.69
Total Assets
472.03
446.82
341.58
343.08
322.19
319.97
327.71
294.62
249.63
257.36

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Cash From Operating Activity
41.15
16.28
38.17
49.21
31.85
21.92
34.94
36.68
32.07
21.94
PBT
18.01
23.64
35.35
21.04
15.41
0.07
22.07
24.94
17.50
5.36
Adjustment
32.43
22.01
22.16
22.01
25.79
26.25
23.82
12.84
20.78
29.04
Changes in Working Capital
-10.36
-26.79
-12.19
6.58
-8.24
0.56
-9.64
2.96
-3.72
-11.32
Cash after chg. in Working capital
40.08
18.86
45.32
49.64
32.96
26.87
36.25
40.73
34.56
23.08
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
1.08
-2.58
-7.15
-0.43
-1.11
-4.96
-1.31
-4.06
-2.49
-1.14
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-39.93
-73.01
-36.20
-14.57
-5.88
-19.41
-20.68
-25.83
-7.24
-11.73
Net Fixed Assets
-33.16
-81.96
-32.76
-15.55
-7.23
-19.28
-22.29
-19.60
21.70
Net Investments
-4.81
-0.05
0.00
-0.10
0.00
-3.54
-4.45
0.00
0.00
Others
-1.96
9.00
-3.44
1.08
1.35
3.41
6.06
-6.23
-28.94
Cash from Financing Activity
-9.10
59.53
0.55
-32.97
-25.97
-2.16
-15.16
-9.80
-25.15
-10.35
Net Cash Inflow / Outflow
-7.88
2.80
2.51
1.66
0.00
0.35
-0.90
1.04
-0.32
-0.14
Opening Cash & Equivalents
9.60
6.42
3.42
1.39
1.46
0.50
1.47
0.42
0.74
0.88
Closing Cash & Equivalent
1.95
9.60
6.42
3.42
1.39
1.46
0.50
1.47
0.42
0.74

Financial Ratios

Consolidated /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Book Value (Rs.)
51.49
49.00
41.12
36.06
32.99
94.84
92.99
84.38
73.25
61.47
ROA
2.65%
4.38%
7.14%
4.37%
2.28%
1.02%
4.93%
7.02%
7.33%
1.95%
ROE
4.97%
7.86%
13.00%
8.65%
4.66%
2.17%
10.73%
15.07%
17.21%
5.29%
ROCE
8.29%
10.11%
16.82%
12.52%
8.70%
5.39%
14.64%
16.46%
14.20%
9.95%
Fixed Asset Turnover
1.40
1.58
2.10
1.93
1.89
1.88
2.70
2.60
2.21
2.43
Receivable days
99.71
97.06
84.61
88.55
83.26
105.81
99.21
118.05
133.84
112.03
Inventory Days
80.76
67.04
59.07
70.95
65.77
73.23
58.02
57.91
55.43
55.29
Payable days
143.40
128.40
127.86
166.10
150.56
175.89
88.19
86.92
85.73
87.08
Cash Conversion Cycle
37.07
35.70
15.82
-6.61
-1.53
3.15
69.04
89.04
103.54
80.25
Total Debt/Equity
0.45
0.44
0.30
0.29
0.50
0.59
0.52
0.60
0.68
0.98
Interest Cover
2.58
4.41
7.34
3.53
1.94
1.01
3.08
3.67
2.67
1.39

Annual Reports:

FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016

News Update:


  • Zim Laboratories completes investment in SIA ZIM Laboratories
    19th Jun 2025, 12:39 PM

    Post investment, the shareholding of the company remains at 100% of the total share capital of SIA ZIM Laboratories

    Read More
  • ZIM Laboratories inks pact with Globalpharma to commercialize oral thin film products
    9th Apr 2025, 18:14 PM

    Under the agreement, Globalpharma will register and commercialize 10 OTF-based Pharmaceutical and Nutraceutical products developed by the company

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.